Navigation Links
Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
Date:4/4/2011

asing heart rate.  However, unlike SNP, CXL-1020 also showed significantly improved heart muscle contraction (inotropy) and relaxation (lusitropy). Moreover, study findings reported that the effects of CXL-1020 were independent from Beta-Adrenergic Receptor and ACE-inhibitor pathways.  Compared to the inotrope dobutamine , CXL-1020 significantly reduced after-load, stroke work and energetic demand, demonstrating its unique, energetically favorable profile.  The researchers conclude that CXL-1020, through its unique mechanism of action, improves heart function in a manner distinct from nitrovasodilators, and that its efficacy will not be reduced with either beta-blockers or ACE inhibitors, medicines commonly prescribed for patients with heart failure.

A Phase I/IIa First in Man Safety and Tolerability Study of a Novel HNO Donor, CXL-1020, in Patients with Stable Congestive Heart Failure. Monday, April 4, 2011; 9:30 a.m. – 12:30 p.m., Ernest N. Morial Convention Center, Hall F; Poster Board #42

The data presented in this poster demonstrates the safety and tolerability of the novel treatment, CXL-1020, in stable congestive heart failure (CHF) patients.  In the double-blind, placebo controlled, randomized, dose escalation study, two cohorts of patients received four sequentially increasing four-hour infusions, at half-log dose increments between 0.1-30 microgram/kg/min with a randomly interspersed placebo. Patient safety was monitored throughout the study. Researchers also evaluated the plasma and urine pharmacokinetics (PK) during treatment and up to 24 hours post dosing.  The results show that CXL-1020 was well tolerated at doses up to 10 microgram/kg/min with no significant change in heart rate or systolic blood pressure, no decrease in kidney function, and no increase in ventricular ectopy.  The PK of CXL-1020 and its by-product were dose-proportional, and greater than 90 percent of the by-product was recovere
'/>"/>

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, ... Global Biotechnology, Inc. for the compounding, packaging and distributing of ... in the United States . ... capable of compounding naltrexone tablets in various strengths for individual ...
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... Feb. 1 Obese teenagers who,succeeded in losing weight ... their bone mineral content increase over that,period, say researchers ... because adolescence is a critical period for bone,health in ... of the journal Obesity studied 62,adolescents between the ages ...
... as part of innovative,Therapeutics Development Initiative, NEW YORK, ... do whatever it takes to speed delivery of transformative,treatments ... Fox,Foundation for Parkinson,s Research has awarded up to $3 ... push potential new PD treatments,closer to the clinic. The ...
Cached Medicine Technology:Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss 2Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss 3Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently delivers ... to have it lead the wedding dress industry into the ... dresses for the global market. , “The CEO of VogueQueen ... focuses on continuing the goal of operational excellence and giving ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... used for prevention of pregnancy for decades and more recently ... that wearing a condom during intercourse may not give good ... and syphilis. ,There has been a rise recently in ... the news may come as a surprise to many. Current ...
... risk of having a pre-term baby may perhaps will like ... that pomegranate juice can prevent brain injury the fetus may ... in case of a pre-term delivery., ,Pomegranate juice contains ... property of neuroprotection and anti-aging effects. ,Researchers from ...
... People may be reacting to varying degrees of energy loss ... // genetic predisposition. How our bodies react to exercise programs ... to exercising like the level of blood glucose in the ... works of scientists from Washington University School of Medicine, exercise ...
... Cancer Society researchers conducted in interesting national survey that ... look at the prevailing myths about cancer in the minds ... 957 adults with no history of cancer to assess their ... identify any associated misconceptions. Participants were asked if five misconceptions ...
... in temperate countries or colder regions of the world would ... Vitamin D in the winter months when the sunlight exposure ... formation of the active component of Vitamin D in the ... bones for later years. The researchers concluded in a study ...
... low birth weight may be at heightened risk// of cardiovascular ... as for the fathers. ,In a research done by ... that leads to low birth weight stems may lead to ... genetic condition coming from the parents. Hence parents of the ...
Cached Medicine News:Health News:Condoms May not be safe Enough 2Health News:Vitamin D Supplement in Teenage Girls essential in Winter months 2
...
...
The Lineage acetabular system with metal liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
Hemisphere modular Cup....
Medicine Products: